Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Common Equity (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Common Equity for 13 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 22.57% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, down 22.57%, and an annual FY2025 reading of $1.2 billion, down 22.57% over the prior year.
  • Common Equity was $1.2 billion for Q4 2025 at Agios Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $2.3 billion in Q1 2021 and bottomed at $660.5 million in Q2 2024.
  • Average Common Equity over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • The sharpest move saw Common Equity skyrocketed 267.29% in 2021, then tumbled 47.43% in 2022.
  • Year by year, Common Equity stood at $1.3 billion in 2021, then fell by 14.8% to $1.1 billion in 2022, then dropped by 26.33% to $811.0 million in 2023, then soared by 90.0% to $1.5 billion in 2024, then dropped by 22.57% to $1.2 billion in 2025.
  • Business Quant data shows Common Equity for AGIO at $1.2 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.4 billion in Q2 2025.